NCT02315612View on ClinicalTrials.gov

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

134

Participants

Timeline

Start Date

December 12, 2014

Primary Completion Date

April 3, 2019

Study Completion Date

October 29, 2024

Conditions

NHLLarge Cell LymphomaFollicular LymphomaALLB-AllB-precursor ALLAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaB-Non Hodgkin LymphomaB-NHL

Interventions

BIOLOGICAL

CD22-CAR

CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02315612 - Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | Biotech Hunter | Biotech Hunter